Cidara Therapeutics Inc
NASDAQ:CDTX
Intrinsic Value
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. [ Read More ]
The intrinsic value of one CDTX stock under the Base Case scenario is 0.75 USD. Compared to the current market price of 13 USD, Cidara Therapeutics Inc is Overvalued by 94%.
Valuation Backtest
Cidara Therapeutics Inc
Run backtest to discover the historical profit from buying and selling CDTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cidara Therapeutics Inc
Current Assets | 57.7m |
Cash & Short-Term Investments | 48.7m |
Receivables | 2.9m |
Other Current Assets | 6.1m |
Non-Current Assets | 5.8m |
PP&E | 4.7m |
Other Non-Current Assets | 1.1m |
Current Liabilities | 35.6m |
Accounts Payable | 3.7m |
Accrued Liabilities | 17.3m |
Other Current Liabilities | 14.6m |
Non-Current Liabilities | 19.8m |
Other Non-Current Liabilities | 19.8m |
Earnings Waterfall
Cidara Therapeutics Inc
Revenue
|
56.5m
USD
|
Cost of Revenue
|
-44.2m
USD
|
Gross Profit
|
12.3m
USD
|
Operating Expenses
|
-44m
USD
|
Operating Income
|
-31.7m
USD
|
Other Expenses
|
300k
USD
|
Net Income
|
-31.4m
USD
|
Free Cash Flow Analysis
Cidara Therapeutics Inc
CDTX Profitability Score
Profitability Due Diligence
Cidara Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Cidara Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
CDTX Solvency Score
Solvency Due Diligence
Cidara Therapeutics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
Cidara Therapeutics Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CDTX Price Targets Summary
Cidara Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CDTX is 5.36 USD with a low forecast of 3.03 USD and a high forecast of 7.35 USD.
Ownership
CDTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CDTX Price
Cidara Therapeutics Inc
Average Annual Return | -17.47% |
Standard Deviation of Annual Returns | 44.17% |
Max Drawdown | -90% |
Market Capitalization | 1.2B USD |
Shares Outstanding | 90 287 400 |
Percentage of Shares Shorted | 0.22% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. The company is headquartered in San Diego, California and currently employs 89 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the discovery, development and commercialization of therapeutics designed for the care of patients facing serious fungal or viral infections. The firm's lead product candidate is rezafungin acetate, an intravenous formulation of an echinocandin. Rezafungin is being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. Rezafungin acetate is in Phase III of chemical trials. Its Cloudbreak antiviral platform consist of pipelines to develop Antiviral Conjugates (AVCs) for the prevention and treatment of influenza and other viral infections, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV) and the SARS-CoV-2 strains causing COVID-19. The firm's subsidiary includes Cidara Therapeutics United Kingdom Limited and Cidara Therapeutics (Ireland) Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one CDTX stock under the Base Case scenario is 0.75 USD.
Compared to the current market price of 13 USD, Cidara Therapeutics Inc is Overvalued by 94%.